Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 86 | SFEBES2022 | Next issue

Society for Endocrinology BES 2022

Harrogate, United Kingdom
14 Nov 2022 - 16 Nov 2022

Card image cap
SfE BES is returning to Harrogate in 2022. Join with endocrine specialists from across the UK and beyond for the Society for Endocrinology's flagship meeting.

Oral Communications

Adrenal and Cardiovascular

ea0086oc4.1 | Adrenal and Cardiovascular | SFEBES2022

Introducing technology to improve patient safety in adrenal insufficiency: a proof-of-concept delivery of a new smartphone app in steroid-dependent patients

Panagiotou Grigorios , Lewis Janet , Sall Seetal , Lansdown Andrew

Introduction: Although significant developments have been achieved in the management of steroid-dependent patients, little progress has been made in ensuring their safety using smartphone technology. We present the use of a novel app in steroid-dependent patients.Methods: A group of unselected individuals currently on steroid replacement due to adrenal insufficiency (AI) were assessed regarding their access to intramuscular (IM) hydrocortisone. A smartph...

ea0086oc4.2 | Adrenal and Cardiovascular | SFEBES2022

Generation of novel tools for the study and development of targeted therapeutic approaches for pheochromocytoma and paraganglioma

Kemkem Yasmine , Santambrogio Alice , Montibus Bertille , Abascal Sherwell Sanchez Carlos , Willis Thea L. , Lodge Emily J. , Yianni Val , Oakey Rebecca J. , Andoniadou Cynthia L.

Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours, which arise from neural crest (NC)-derived structures: the adrenal medulla and the paraganglia. Around one third of PPGLs are associated with inherited cancer susceptibility genes, the highest rate among all tumour types. Currently, the only diagnostic criterion for malignant disease is the presence of metastasis and no molecular or histological features have been identified that help predict risk. A...

ea0086oc4.3 | Adrenal and Cardiovascular | SFEBES2022

Plasma steroid concentrations reflect disease severity during acute illness but not recovery after hospitalisation with COVID-19

Devine Kerri , Walker Brian R , Homer Natalie ZM , Openshaw Peter JM , Kenneth Baillie J. , Andrew Ruth , Wain Louise V , Semple Malcolm G , Reynolds Rebecca M

Background: Endocrine systems are known to be disrupted in acute illness, and we previously demonstrated that plasma steroid concentrations correlated with severity in patients hospitalised with COVID-19. Given their similarity to some clinical hormone deficiencies, we hypothesised that ‘long-COVID’ symptoms may be related to ongoing endocrine dysfunction.Methods: Plasma steroids, precursors and metabolites were quantified by LCMS/MS in multi-c...

ea0086oc4.4 | Adrenal and Cardiovascular | SFEBES2022

Steroid and global metabolome in benign adrenal tumours with mild autonomous cortisol secretion: analysis by mass spectrometry and machine learning to understand metabolic risk

Prete Alessandro , Abdi Lida , Canducci Marco , Taylor Angela E. , Bancos Irina , Gilligan Lorna C. , Jenkinson Carl , Albors-Zumel Ariadna , van den Brandhof Elina , Zhang Yuanqing , Chortis Vasileios , Tsagarakis Stylianos , Lang Katharina , Macech Magdalena , Delivanis Danae A. , Pupovac Ivana D. , Reimondo Giuseppe , Marina Ljiljana V. , Deutschbein Timo , Balomenaki Maria , O'Reilly Michael W. , Bednarczuk Tomasz , Zhang Catherine D. , Dusek Tina , Diamantopoulos Aristidis , Asia Miriam , Kondracka Agnieszka , Li Dingfeng , Masjkur Jimmy R. , Quinkler Marcus , Ueland Grethe AE. , Conall Dennedy M. , Beuschlein Felix , Tabarin Antoine , Fassnacht Martin , Ivovic Miomira , Terzolo Massimo , Kastelan Darko , Young Jr William F. , Manolopoulos Konstantinos M. , Ambroziak Urszula , Vassiliadi Dimitra A. , Sitch Alice J. , Tino Peter , Biehl Michael , Dunn Warwick B. , Arlt Wiebke

Background: Benign adrenal tumours are found in 3-10% of adults and can be non-functioning (NFAT) or associated with adrenal hormone excess. Analysing 1305 prospectively recruited patients with benign adrenal tumours, we recently demonstrated that 45% had mild autonomous cortisol secretion (MACS), i.e. biochemical cortisol excess without signs of Cushing’s syndrome (CS). MACS increases the prevalence and severity of hypertension and type 2 diabetes (Ann Int Med. 2022 Doi:...

ea0086oc4.5 | Adrenal and Cardiovascular | SFEBES2022

Comparison of prednisolone and modified-release hydrocortisone capsules in the treatment of congenital adrenal hyperplasia: dose and disease control

Rees Aled , Merke Deborah , Arlt Wiebke , Pierriere Aude , Hirschberg Angelica , Juul Anders , Newell-Price John , Perry Colin , Prete Alessandro , Reisch Nicole , Stikkelbroeck Monica , Touraine Philippe , Coope Helen , Lewis Alexander , Porter John , Ross Richard

Introduction: First-line treatment for congenital adrenal hyperplasia (CAH) is hydrocortisone1. When adequate control is not achieved, prednisolone (or its prodrug prednisone) are often used. However, there has been no formal comparison of disease control in CAH comparing prednis(ol)one vs hydrocortisone and patients are often on a glucocorticoid dose that exceeds the guideline recommended dose of hydrocortisone (≤25 mg/day)1,2. We report an interim...

ea0086oc4.6 | Adrenal and Cardiovascular | SFEBES2022

Glucocorticoid excess elevates metabolic rate via a 11β-HSD1 dependent mechanism in C57BL/6J mice

Heaselgrave Samuel , Heising Silke , Morgan Stuart , Kabli Ali , Sagmeister Michael , Hardy Rowan , Doig Craig , Morton Nicholas , Tsintzas Kostas , Lavery Gareth

Introduction: Glucocorticoids are vital metabolic regulators. However, glucocorticoid excess (GE) causes severe metabolic dysfunction, ultimately leading to Cushing’s Syndrome. This dysfunction is often dependent on the presence of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Whether GE also alters metabolic rate, and whether this is also dependent on 11β-HSD1, remains unclear.Methods: Male and female wild-type (WT) ...